Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Development of Parkinson Disease and Its Relationship with Incidentally Discovered White Matter Disease and Covert Brain Infarction in a Real‐World Cohort
Kent, David M. , Leung, Lester Y. , Puttock, Eric J. , Kallmes, David F. , Nelson, Jason , Vickery, Ellen M. , Chen, Wansu , Noyce, Alastair J , Kent, David M , Wang, Andy Yu-Der , Luetmer, Patrick H. , Fu, Sunyang , Zheng, Chengyi , Liu, Hongfang , Noyce, Alastair J.

Mayo Clinic

Annals of Neurology | July 22, 2022 | Volume: 92 | Issue: 4 | Pages: 620-630

10.1002/ana.26458 | PMID 35866711 Get It

Objective This study aimed to examine the relationship between covert cerebrovascular disease, comprised of covert brain infarction and white matter disease, discovered incidentally in routine care, and subsequent Parkinson disease. Methods Patients were ≥50 years and received neuroimaging for non‐stroke indications in the Kaiser Permanente Southern California system from 2009 to 2019. Natural language processing identified incidentally discovered covert brain infarction and white matter disease and classified white matter disease severity. The Parkinson disease outcome was defined as 2 ICD diagnosis codes. Results 230,062 patients were included (median follow‐up 3.72 years). A total of 1,941 Parkinson disease cases were identified (median time‐to‐event 2.35 years). Natural language processing identified covert cerebrovascular disease in 70,592 (30.7%) patients, 10,622 (4.6%) with covert brain infarction and 65,814 (28.6%) with white matter disease. After adjustment for known risk factors, white matter disease was associated with Parkinson disease (hazard ratio 1.67 [95%CI, 1.44, 1.93] for patients <70 years and 1.33 [1.18, 1.50] for those ≥70 years). Greater severity of white matter disease was associated with increased incidence of Parkinson disease(/1,000 person‐years), from 1.52 (1.43, 1.61) in patients without white matter disease to 4.90 (3.86, 6.13) in those with severe disease. Findings were robust when more specific definitions of Parkinson disease were used. Covert brain infarction was not associated with Parkinson disease (adjusted hazard ratio = 1.05 [0.88, 1.24]). Interpretation Incidentally discovered white matter disease was associated with subsequent Parkinson disease, an association strengthened with younger age and increased white matter disease severity. Incidentally discovered covert brain infarction did not appear to be associated with subsequent Parkinson disease. ANN NEUROL 2022;92:620–630
ACE2 and TMPRSS2 SARS-CoV-2 infectivity genes: deep mutational scanning and characterization of missense variants
Zhang, Lingxin , Sarangi, Vivekananda , Liu, Duan , Ho, Ming‐Fen , Grassi, Angela R, Moon, Irene, Larson, Nicholas B. , Athreya, Arjun P. , Wang, Liewei , Weinshilboum, Richard M. , Larson, Nicholas B , Weinshilboum, Richard, Liu, Duan , Ho, Ming-Fen , Wei, Lixuan , Vierkant, Robert A. , Lazaridis, Konstantinos N. , Weinshilboum, Richard M.

Mayo Clinic

Human Molecular Genetics | July 21, 2022 | Volume: 31 | Issue: 24 | Pages: 4183-4192

10.1093/hmg/ddac157 | PMID 35861636 Get It

Abstract The human angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) proteins play key roles in the cellular internalization of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus responsible for the coronavirus disease of 2019 (COVID-19) pandemic. We set out to functionally characterize the ACE2 and TMPRSS2 protein abundance for variant alleles encoding these proteins that contained non-synonymous single-nucleotide polymorphisms (nsSNPs) in their open reading frames (ORFs). Specifically, a high-throughput assay, deep mutational scanning (DMS), was employed to test the functional implications of nsSNPs, which are variants of uncertain significance in these two genes. Specifically, we used a ‘landing pad’ system designed to quantify the protein expression for 433 nsSNPs that have been observed in the ACE2 and TMPRSS2 ORFs and found that 8 of 127 ACE2, 19 of 157 TMPRSS2 isoform 1 and 13 of 149 TMPRSS2 isoform 2 variant proteins displayed less than ~25% of the wild-type protein expression, whereas 4 ACE2 variants displayed 25% or greater increases in protein expression. As a result, we concluded that nsSNPs in genes encoding ACE2 and TMPRSS2 might potentially influence SARS-CoV-2 infectivity. These results can now be applied to DNA sequence data for patients infected with SARS-CoV-2 to determine the possible impact of patient-based DNA sequence variation on the clinical course of SARS-CoV-2 infection.
Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
Khurana, Arushi , Mwangi, Raphael , Link, Brian K. , Wang, Yucai , Feldman, Andrew L. , Thompson, Carrie A. , Novak, Anne J. , Villasboas, José C. , Thanarajasingam, Gita , Farooq, Umar , Syrbu, Sergei , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Link, Brian K , Wang, Yucai , Feldman, Andrew L , Novak, Anne J , Villasboas, Jose Caetano , Farooq, Umar , Witzig, T.E. , Cerhan, James R , Maurer, Matthew , Syrbu, Sergei , Tun, Aung M. , Witzig, Thomas E. , Rimsza, Lisa M. , Cerhan, James R. , Habermann, Thomas M. , Maurer, Matthew J.

Mayo Clinic

Blood Advances | July 18, 2022 | Volume: 6 | Issue: 17 | Pages: 5210-5221

10.1182/bloodadvances.2022007990 | PMID 35849723 Get It

Abstract Low-grade B-cell lymphomas other than follicular and small lymphocytic lymphoma (LGBCL) account for 10% of all B-cell non-Hodgkin lymphomas. Despite improvements in survival outcomes for these patients, little is known about cause of death (COD) in the rituximab era. For a better understanding, we studied 822 newly diagnosed patients with marginal zone, lymphoplasmacytic, and unclassifiable low-grade B-cell lymphoma prospectively enrolled in the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource from 2002 to 2015. COD was assigned based on medical record review using a standard protocol. At a median follow-up of 107 months, 219 (27%) patients had died. The incidence of lymphoma-related deaths when pooling across subtypes was lower than non–lymphoma-related deaths (10-year incidence, 8.0%; 95% confidence interval [CI]: 6.2-10.4 vs 13.6%; 95% CI: 11.2-16.6). The incidence of lymphoma-related deaths varied by subtype, ranging from 3.7% at 10 years in extranodal marginal zone lymphoma to 19.3% in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Patients with early progression or retreatment events, defined using event-free survival at 24 months from diagnosis, had significantly higher likelihood of lymphoma-related death compared with patients without early events (10-year estimate: 19.1% vs 5.1%, respectively; P &lt; .001), whereas the rates for non–lymphoma-related death were comparable in patients with or without early events (10-year estimates: 11.0% vs 15.3%, respectively). In conclusion, the most common COD in LGBCLs in the first decade after diagnosis was for causes other than lymphoma. Progression or retreatment within the first 2 years of diagnosis was a strong predictor for risk of lymphoma-related death.
Venetoclax Plus Gilteritinib for FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia
Daver, Naval , Perl, Alexander E. , Maly, Joseph, Ritchie, Ellen K. , Litzow, Mark R. , McCloskey, James, Smith, Catherine C. , Schiller, Gary J. , Bradley, Terrence, Tiu, Ramón V., Naqvi, Kiran , Brackman, Deanna J. , Siddani, Satya R., Wang, Jing , Chyla, Brenda , Lee, Paul , Altman, Jessica K. , Litzow, Mark R. , Smith, Catherine C , Dail, Monique , Chyla, Brenda , Altman, Jessica K , Daver, Naval , Levis, Mark J. , Dail, Monique

Mayo Clinic

Journal of Clinical Oncology | July 18, 2022 | Volume: 40 | Issue: 35 | Pages: 4048-4059

10.1200/jco.22.00602 | PMID 35849791 Get It

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated ( FLT3 mut ) acute myeloid leukemia (AML) but seldom reduces FLT3 mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetoclax in preclinical models of FLT3 mut AML. METHODS This phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505 ) enrolled patients with FLT3 wild-type and FLT3 mut (escalation) or FLT3 mut (expansion) relapsed/refractory AML. Patients received 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The primary objectives were safety, identification of the recommended phase II dose, and the modified composite complete response (mCRc) rate (complete response [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery + morphologic leukemia-free state) using ADMIRAL phase III–defined response criteria. RESULTS Sixty-one patients were enrolled (n = 56 FLT3 mut ); 64% (n = 36 of 56) of FLT3 mut patients had received prior FLT3 inhibitor therapy. The recommended phase II dose was 400 mg venetoclax once daily and 120 mg gilteritinib once daily. The most common grade 3/4 adverse events were cytopenias (n = 49; 80%). Adverse events prompted venetoclax and gilteritinib dose interruptions in 51% and 48%, respectively. The mCRc rate for FLT3 mut patients was 75% (CR, 18%; CR with incomplete blood count recovery, 4%; CR with incomplete platelet recovery, 18%; and morphologic leukemia-free state, 36%) and was similar among patients with or without prior FLT3 inhibitor therapy (80% v 67%, respectively). The median follow-up was 17.5 months. The median time to response was 0.9 months, and the median remission duration was 4.9 months (95% CI, 3.4 to 6.6). FLT3 molecular response (< 10 −2 ) was achieved in 60% of evaluable mCRc patients (n = 15 of 25). The median overall survival for FLT3 mut patients was 10.0 months. CONCLUSION The combination of venetoclax and gilteritinib was associated with high mCRc and FLT3 molecular response rates regardless of prior FLT3 inhibitor exposure. Dose interruptions were needed to mitigate myelosuppression.
Including diverse and admixed populations in genetic epidemiology research
Caliebe, Amke , Tekola‐Ayele, Fasil , Darst, Burcu F. , Wang, Xuexia , Song, Yeunjoo E. , Sebro, Ronnie , Balding, David J. , Saad, Mohamad , Dubé, Marie‐Pierre , Sebro, Ronnie A, Dubé, Marie-Pierre , Darst, Burcu F , Gui, Jiang

Mayo Clinic

Genetic Epidemiology | July 17, 2022 | Volume: 46 | Issue: 7 | Pages: 347-371

10.1002/gepi.22492 | PMID 35842778 Get It

AbstractThe inclusion of ancestrally diverse participants in genetic studies can lead to new discoveries and is important to ensure equitable health care benefit from research advances. Here, members of the Ethical, Legal, Social, Implications (ELSI) committee of the International Genetic Epidemiology Society (IGES) offer perspectives on methods and analysis tools for the conduct of inclusive genetic epidemiology research, with a focus on admixed and ancestrally diverse populations in support of reproducible research practices. We emphasize the importance of distinguishing socially defined population categorizations from genetic ancestry in the design, analysis, reporting, and interpretation of genetic epidemiology research findings. Finally, we discuss the current state of genomic resources used in genetic association studies, functional interpretation, and clinical and public health translation of genomic findings with respect to diverse populations.
Combined ibrutinib and venetoclax for treatment of patients with ibrutinib‐resistant or double‐refractory chronic lymphocytic leukaemia
Hampel, Paul J. , Rabe, Kari G. , Call, Timothy G. , Leis, José F., Kenderian, Saad S. , Muchtar, Eli , Wang, Yucai , Koehler, Amber B. , Parrondo, Ricardo , Schwager, Susan M., Braggio, Esteban , Kenderian, Saad Sirop , Muchtar, E , Wang, Yucai , Parrondo, Ricardo D , Shi, Min , Parikh, Sameer A , Chaffee, Kari G. , Braggio, Esteban , Ding, Wei , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

British Journal of Haematology | July 16, 2022 | Volume: 199 | Issue: 2 | Pages: 239-244

10.1111/bjh.18357 | PMID 35841338 Get It

SummaryPatients with chronic lymphocytic leukaemia (CLL) disease progression on ibrutinib or after sequential ibrutinib and venetoclax‐based treatments (double‐refractory) have poor outcomes. In this retrospective study, we analysed outcomes with combined ibrutinib and venetoclax treatment in these groups of patients. The median treatment‐free and overall survival for 22 patients with prior progression on ibrutinib (venetoclax‐naïve) were 23.7 and 47.1 months respectively. In 11 patients with double‐refractory CLL, the median treatment‐free and overall survival were 11.2 and 27.0 months respectively. The combination of ibrutinib and venetoclax may help bridge the current gap in options for patients with disease refractory to the most commonly used novel agents.
Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia
Yu, Ming , Moinova, Helen , Willbanks, Amber, Cannon, Victoria K., Wang, Ting , Carter, Kelly , Kaz, Andrew M. , Reddi, Deepti , Inadomi, John M. , Luebeck, E. Georg , Iyer, Prasad G. , Wang, Jean S. , Shaheen, Nicholas J. , Thota, Prashanti N., Willis, Joseph , LaFramboise, Thomas , Chak, Amitabh , Markowitz, Sanford D. , Moinova, Helen R , Inadomi, John , Luebeck, Georg , Shaheen, Nicholas J , Chak, Amitabh , Grady, William M , Willis, Joseph E , Carter, Kelly , Cannon, Victoria K., Reddi, Deepti , Canto, Marcia Irene , Grady, William M.

Mayo Clinic

Clinical Cancer Research | July 15, 2022 | Volume: 28 | Issue: 17 | Pages: 3761-3769

10.1158/1078-0432.ccr-22-0445 | PMID 35705525 Get It

Abstract Purpose: Current endoscopy-based screening and surveillance programs have not been proven effective at decreasing esophageal adenocarcinoma (EAC) mortality, creating an unmet need for effective molecular tests for early detection of this highly lethal cancer. We conducted a genome-wide methylation screen to identify novel methylation markers that distinguish EAC and high-grade dysplasia (HGD) from normal squamous epithelium (SQ) or nondysplastic Barrett's esophagus (NDBE). Experimental Design: DNA methylation profiling of samples from SQ, NDBE, HGD, and EAC was performed using HM450 methylation arrays (Illumina) and reduced-representation bisulfate sequencing. Ultrasensitive methylation-specific droplet digital PCR and next-generation sequencing (NGS)-based bisulfite-sequencing assays were developed to detect the methylation level of candidate CpGs in independent esophageal biopsy and endoscopic brushing samples. Results: Five candidate methylation markers were significantly hypermethylated in HGD/EAC samples compared with SQ or NDBE (P &lt; 0.01) in both esophageal biopsy and endoscopic brushing samples. In an independent set of brushing samples used to construct biomarker panels, a four-marker panel (model 1) demonstrated sensitivity of 85.0% and 90.8% for HGD and EACs respectively, with 84.2% and 97.9% specificity for NDBE and SQ respectively. In a validation set of brushing samples, the panel achieved sensitivity of 80% and 82.5% for HGD and EAC respectively, at specificity of 67.6% and 96.3% for NDBE and SQ samples. Conclusions: A novel DNA methylation marker panel differentiates HGD/EAC from SQ/NDBE. DNA-methylation–based molecular assays hold promise for the detection of HGD/EAC using esophageal brushing samples.
Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia
Wang, Liping , Lin, Guang , Zuo, Zhongyuan , Li, Yarong , Byeon, Seul Kee , Pandey, Akhilesh , Bellen, Hugo J. , Pandey, Akhilesh , Bellen, Hugo J , Byeon, Seul Kee

Mayo Clinic

Science Advances | July 13, 2022 | Volume: 8 | Issue: 28 | Pages: No page available

10.1126/sciadv.abn3326 | PMID 35857503 Get It

Recessive variants in GBA1 cause Gaucher disease, a prevalent form of lysosome storage disease. GBA1 encodes a lysosomal enzyme that hydrolyzes glucosylceramide (GlcCer) into glucose and ceramide. Its loss causes lysosomal dysfunction and increased levels of GlcCer. We generated a null allele of the Drosophila ortholog Gba1b by inserting the Gal4 using CRISPR-Cas9. Here, we show that Gba1b is expressed in glia but not in neurons. Glial-specific knockdown recapitulates the defects found in Gba1b mutants, and these can be rescued by glial expression of human GBA1 . We show that GlcCer is synthesized upon neuronal activity, and it is transported from neurons to glia through exosomes. Furthermore, we found that glial TGF-β/BMP induces the transfer of GlcCer from neurons to glia and that the White protein, an ABCG transporter, promotes GlcCer trafficking to glial lysosomes for degradation.
The landscape of metabolic brain alterations in Alzheimer's disease
Batra, Richa , Arnold, Matthias , Wörheide, Maria A. , Allen, Mariet , Wang, Xue , Blach, Colette , Levey, Allan I. , Seyfried, Nicholas T. , Ertekin‐Taner, Nilüfer , Bennett, David A. , Krumsiek, Jan , Krumsiek, Jan , Bennett, David A. , Arnold, Matthias , Levey, Allan I , Kastenmüller, Gabi , Kaddurah‐Daouk, Rima

Mayo Clinic

Alzheimer's & Dementia | July 13, 2022 | Volume: 19 | Issue: 3 | Pages: 980-998

10.1002/alz.12714 | PMID 35829654 Get It

Abstract Introduction Alzheimer's disease (AD) is accompanied by metabolic alterations both in the periphery and the central nervous system. However, so far, a global view of AD‐associated metabolic changes in the brain has been missing. Methods We metabolically profiled 500 samples from the dorsolateral prefrontal cortex. Metabolite levels were correlated with eight clinical parameters, covering both late‐life cognitive performance and AD neuropathology measures. Results We observed widespread metabolic dysregulation associated with AD, spanning 298 metabolites from various AD‐relevant pathways. These included alterations to bioenergetics, cholesterol metabolism, neuroinflammation, and metabolic consequences of neurotransmitter ratio imbalances. Our findings further suggest impaired osmoregulation as a potential pathomechanism in AD. Finally, inspecting the interplay of proteinopathies provided evidence that metabolic associations were largely driven by tau pathology rather than amyloid beta pathology. Discussion This work provides a comprehensive reference map of metabolic brain changes in AD that lays the foundation for future mechanistic follow‐up studies.
Geometric structure guided model and algorithms for complete deconvolution of gene expression data
Chen, Duan, Li, Shaoyu , Wang, Xue

Mayo Clinic

Foundations of Data Science | July 12, 2022 | Volume: 4 | Issue: 3 | Pages: 441

10.3934/fods.2022013 | PMID 38250319 Get It

<p style='text-indent:20px;'>Complete deconvolution analysis for bulk RNA-seq data is important and helpful to distinguish whether the differences of disease-associated GEPs (gene expression profiles) in tissues of patients and normal controls are due to changes in cellular composition of tissue samples, or due to GEPs changes in specific cells. One of the major techniques to perform complete deconvolution is nonnegative matrix factorization (NMF), which also has a wide-range of applications in the machine learning community. However, the NMF is a well-known strongly ill-posed problem, so a direct application of NMF to RNA-seq data will suffer severe difficulties in the interpretability of solutions. In this paper, we develop an NMF-based mathematical model and corresponding computational algorithms to improve the solution identifiability of deconvoluting bulk RNA-seq data. In our approach, we combine the biological concept of marker genes with the solvability conditions of the NMF theories, and develop a geometric structures guided optimization model. In this strategy, the geometric structure of bulk tissue data is first explored by the spectral clustering technique. Then, the identified information of marker genes is integrated as solvability constraints, while the overall correlation graph is used as manifold regularization. Both synthetic and biological data are used to validate the proposed model and algorithms, from which solution interpretability and accuracy are significantly improved.</p>